
Lexeo Therapeutics shares surge 25% on interim data for LX2020 gene therapy
Investing.com -- Lexeo Therapeutics (NASDAQ: LXEO) shares surged 25% on Monday after interim clinical trial results showed substantial reductions in abnormal heart rhythms among patients receiving its experimental gene therapy, while regulatory feedback provided a potential pathway toward accelerated approval.
Participants in the high-dose cohorts recorded an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) and a 44% mean reduction in premature ventricular contractions (PVCs) at the latest assessment, compared with baseline. Six of seven participants showed improvement in NSVT, while five of seven improved in PVC burden. Five also reported improvements in symptoms. Ten participants have been dosed in the trial in total, nine of them with at least 12 months of follow-up; the headline efficacy figures are from the seven high-dose participants.
"These data further strengthen our confidence in LX2020 and its potential to address the underlying biology of PKP2-ACM," said











